Hostname: page-component-84b7d79bbc-g5fl4 Total loading time: 0 Render date: 2024-07-26T07:27:21.378Z Has data issue: false hasContentIssue false
  • English
  • Français

What a difference a state makes: pharmaceutical innovation after the TRIPs agreement

Published online by Cambridge University Press:  20 January 2017

Verena Schüren
Get access Rights & Permissions [Opens in a new window]

Abstract

For more than a decade, political science scholars have stressed the harmonizing effect of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs). Recent implementation practices in developing countries, however, have challenged this view. In this article, I argue that different manifestations of innovation systems can lead to varying patterns of innovation. I substantiate this claim through a comparison between the pharmaceutical sectors of India and Brazil. Drawing on the NSI approach, my analysis reveals that different forms of state engagement have played a decisive role for the varying directions of post-TRIPs pharmaceutical innovation in the two countries. The article illustrates that developing countries can opt for different approaches to innovation even after TRIPs and that the socioeconomic effects of global IP regimes can only be assessed properly when taking into account the country-specific configurations of national innovation systems.

Type
Research Article
Information
Business and Politics , Volume 15 , Issue 2 , August 2013 , pp. 217 - 243
Copyright
Copyright © V.K. Aggarwal 2013 and published under exclusive license to Cambridge University Press 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abrol, D. 2006. “The Challenge of Transformation of Indian System(s) of Innovation.” In Proceedings of the Globelics India Conference (“Innovation Systems for Competitiveness and Shared Prosperity in Developing Countries”). Kerala, India.Google Scholar
Alger, J., Becerra-Posada, F., Kennedy, A., Martinell, E. and Cuervo, L. G. 2009. “National Health Research Systems in Latin America: A 14-Country Review.” Pan American Journal of Public Health 26: 447–457.Google Scholar
Altenburg, T. 2009. “Building Inclusive Innovation Systems in Developing Countries: Challenges for IS Research.” In Handbook of Innovation Systems and Developing Countries, edited by Lundvall, B.-Å., Joseph, K. J. and Chaminade, C., 33–56. Cheltenham & Northhampton, MA: Edward Elgar.Google Scholar
Amable, B. 2000. “Institutional Complementarity and Diversity of Social Systems of Innovation and Production.” Review of International Political Economy 7: 645–687.CrossRefGoogle Scholar
Barton, J., Alexander, D., Correa, C., Mashelkar, R., Samuels, G. and Thomas, S. 2002. Integrating Intellectual Property Rights and Development Policy (Report of the Commission on Intellectual Property Rights). London: Commission on Intellectual Property Rights.Google Scholar
Biehl, J. 2004. “The Activist State. Global Pharmaceuticals, Aids and Citizenship in Brazil.” Social Text 22: 105–132.CrossRefGoogle Scholar
Cassier, M. and Correa, M. 2007. “Intellectual Property and Public Health: Coping of HIV/Aids Drugs by Brazilian Public and Private Pharmaceutical Laboratories.” Electronic Journal of Communication, Information and Innovation in Health 1: 83–90.Google Scholar
Chamas, C. I. 2005. “Developing Innovative Capacity in Brazil to Meet Health Needs.” MIHR Report to CIPH WHO ref. CIPH Study 10d (DGR): 75–108.Google Scholar
Chataway, J., Tait, J. and Wield, D. 2007. “Frameworks for Pharmaceutical Innovation in Developing Countries – the Case of Indian Pharma.” Technology Analysis & Strategic Management 19: 697–708.Google Scholar
Chaudhuri, S. 2007. “The Gap Between Successful Innovation and Access to Its Benefits: Indian Pharmaceuticals.” The European Journal of Development Research 19: 49–65.Google Scholar
Chaudhuri, S. 2008. “Is Product Patent Protection Necessary to Spur Innovation in Developing Countries?.” In The Development Agenda, Global Intellectual Property and Developing Countries. Neil Weinstock.Google Scholar
Cohen, J. C. and Lybecker, K. M. 2005. “Aids Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health.” The World Economy 28: 211–230.Google Scholar
Correa, C. M. 2011. “Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing.” South Centre Research Papers, No. 41.Google Scholar
Cozzens, S., Gatchair, S. and Thakur, D. 2006. “Distributional Assessment of Emerging Technologies. A Framework Analysis.” James Martin Institute Working Paper 1. Georgia Institute of Technology.Google Scholar
Cozzens, S. E. and Kaplinsky, R. 2009. “Innovation, Poverty and Inequality: Cause, Coincidence, or Co-Evolution?.” In Handbook of Innovation Systems and Developing Countries, edited by Lundvall, B.-A., Joseph, K. J., Chaminade, C. and Vang, J., 57–82. Cheltenham and Northhampton: Edward Elgar.Google Scholar
Dahlman, C. 2010. “Innovation Strategies in Brazil, China and India: From Imitation to Deepening Technological Capability in the South.” In The Rise of Technological Power in the South, edited by Fu, X. and Soete, L., 15–48. Houndsmills, Basingstoke, Hampshire: Palgrave Macmillan.Google Scholar
Damodaran, A. 2008. “Indian Patent Law in the Post-Trips Decade: S & T Policy Appraisal.” Journal of Intellectual Property Rights 13: 414–423.Google Scholar
de Brito Cruz, C. H. and de Mello, L. 2006. “Boosting Innovation Performance in Brazil.” OECD Economics Department Working Papers from OECD Publishing, 532.Google Scholar
Deere, C. 2009. The Implementation Game: The TRIPs Agreement and the Global Politics of Intellectual Property Reform in Developing Countries. Oxford: Oxford University Press.Google Scholar
DIPP (Department of Industrial Policy & Promotion). 2010. Compulsory Licencing, Discussion Paper, April 17, 2013.Google Scholar
Doctor, M. 2009. Furthering Industrial Development in Brazil: Globalisation and the National Innovation System. Rio de Janeiro: Latin American Studies Association.Google Scholar
Drahos, P. 2004. “The Regulation of Public Goods.” Journal of International Economic Law 7: 321–339.Google Scholar
Drahos, P. 2007. “Trust Me: Patent Offices in Developing Countries.” Australian National University Working Paper, 11.Google Scholar
Edquist, C. 2005. “Systems of Innovation – Perspectives and Challenges.” In Oxford Handbook of Innovation, edited by Fagerberg, J., Mowery, D. and Nelson, R., 181–208. Oxford: Oxford University Press.Google Scholar
Eimer, T. and Lütz, S. 2010. “Developmental States, Civil Society, and Public Health: Patent Regulation for HIV/Aids Pharmaceuticals in India and Brazil.” Regulation and Governance 4: 135–153.Google Scholar
Eimer, Thomas R., Lütz, S. and Schüren, V. 2013. “Norm Diffusion through Advocacy Coalitions: Implementing International Intellectual Property Norms in India and Brazil.” Paper presented at the ISA 54th Annual Convention, April, San Francisco.Google Scholar
Eren-Vural, I. 2007. “Domestic Contours of Global Regulation, Understanding the Policy Changes on Pharmaceutical Patents in India and Turkey.” Review of International Political Economy 14: 105–142.Google Scholar
Ernst, D. 2002. “Global Production Networks and the Changing Geography of Innovation Systems: Implications for Developing Countries.” Economics of Innovation and New Technology 11: 497–523.Google Scholar
Ferrer, M., Thorsteinsdóttir, H., Quach, U., Singer, P. A. and Daar, A. S. 2004. “The Scientific Muscle of Brazil's Health Biotechnology.” Nature Biotechnology 22: DC8–DC12.Google Scholar
Floricel, S., Michela, J. and George, M. 2009. “Resource Feedbacks for Continuous Innovation: The Articulation of Firm, University, and Government Rules.” Paper to be presented at the CBS Summer Conference, 17–19 June 2009, Copenhagen.Google Scholar
Freeman, C. 1982. The Economics of Industrial Innovation. 2nd ed. Cambridge: MIT Press.Google Scholar
Flynn, M. 2008. “Public Production of Anti-Retroviral Medicines in Brazil, 1990–2007.” Development and Change 39: 513–536.Google Scholar
Giugale, M. 2011, July 5. “Yes, They Can: How Emerging Economies Are Building Universal Health Coverage.” Accessed April 23, 2012. http://www.huffingtonpost.com/marcelo-giugale/developing-countries-universal-healthcare_b_1018240.html.Google Scholar
Gopakumar, K. M. 2010. “India: A Critical Review of the Implementation of Trips Patent Regime.” The Law and Development Review 3: 324–368.Google Scholar
Federal, Governo. 2003. Diretrizes De Política Industrial, Tecnológica E De Comércio Exterior.Google Scholar
Guennif, S. and Ramani, S. V. 2012. “Explaining Divergence in Catching-up in Pharma between India and Brazil using the NSI-Framework.” Research Policy 41: 430–441.Google Scholar
Halbert, D. J. 1999. Intellectual Property in the Information Age. The Politics of Expanding Ownership Rights. Westport, Connecticut: Quorum Books.Google Scholar
Hasenclever, L. and Paranhos, J. 2009. The Development of the Pharmaceutical Industry in Brazil and India: Technological Capability and Industrial Development. Mimeo.Google Scholar
Horner, R. 2013. “The Impact of Patents on Innovation, Technology Transfer and Health: A Pre- and Post-TRIPs Analysis of India's Pharmaceutical Industry.” New Political Economy 1–25. DOI:10.1080/13563467.2013.796446 [Epub Ahead of Print].Google Scholar
ICMR (Indian Council of Medical Research). 2008. Guidelines for Good Clinical Laboratory Practices (Gclp). New Delhi.Google Scholar
Interview 146 Representative of the Indian Ministry of Commerce and Industry. New Delhi, March 3, 2011.Google Scholar
Interview 154 Indian civil society representative. New Delhi, February 23, 2011.Google Scholar
Interview 156 Representative of an Indian pharmaceutical industry association. New Delhi, February 27, 2011.Google Scholar
Interview 166 Representative of the ENSP. Rio de Janeiro, July 25, 2011.Google Scholar
Interview 226 Representative of Fiocruz. Rio de Janeiro, August 31, 2011.Google Scholar
Interview 227 Representative of the Brazilian Ministry of Health. Brasília, August 11, 2011.Google Scholar
Interview 235 Representative of a Brazilian industry association. Sao Paulo, August 22, 2011.Google Scholar
Interview 236 Representative of Fiocruz, Rio de Janeiro, September 2, 2011.Google Scholar
Interview 245 Representative of the Brazilian Ministry of Health, CIS. Brasília, August 15, 2011.Google Scholar
Interview 246 Representative of the Brazilian Ministry of Foreign Affairs, Itamaraty. Brasília, August 6, 2011.Google Scholar
Interview 253 Representative of the Brazilian Ministry of Health. Brasília, August 5, 2011.Google Scholar
Interview 255 Representative of the Brazilian Ministry of Health. Brasília, August 10, 2011.Google Scholar
Interview 275 Representative of the Indian Council of Science & Industrial Research. New Delhi, February 7, 2012.Google Scholar
Interview 276 Former representative of the Indian Ministry of Commerce and Industry. New Delhi, February 8, 2012.Google Scholar
Interview 278 Representative of the Jawaharlal Nehru University, Centre for Studies in Science Policy. New Delhi, February 9, 2012.Google Scholar
Interview 279 Former representative of the Indian Ministry of Science and Technology. New Delhi, February 10, 2012.Google Scholar
Interview 280 Indian civil society representative, New Delhi, February 10, 2012.Google Scholar
Interview 283 Representative of the Indian Ministry of Health. New Delhi, February 13, 2012.Google Scholar
Interview 284 Representative of the Public Health Foundation of India. New Delhi, February 14, 2012.Google Scholar
Interview 295 Representative of the Pharmacy Council of India. New Delhi, February 15, 2012.Google Scholar
Interview 299 Representative of an Indian clinical research organization. New Delhi, February 17, 2012.Google Scholar
Interview 300 Representative of the Indian Council of Science & Industrial Research. New Delhi, February 21, 2012.Google Scholar
Interview 313 Representative of the Indian Council of Medical Research. New Delhi, February 23, 2012.Google Scholar
Interview 320 Representative of the Indian Ministry of Commerce and Industry. New Delhi, February 24, 2012.Google Scholar
Interview 322 Representative of the National Institute of Pharmaceutical Education and Research. Chandigarh, February 27, 2012.Google Scholar
Interview 324 Representative of the National Institute of Pharmaceutical Education and Research. Chandigarh, February 27, 2012.Google Scholar
Jeffrey, R. and Santhosh, M. 2009. “Architecture of Drug Regulation in India. What are the Barriers to Regulatory Reform?.” Journal of Health Studies 2: 13–31.Google Scholar
Joshi, H. N. 2003. “Analysis of the Indian Pharmaceutical Industry: With Emphasis on Opportunities in 2005.” Pharmaceutical Technology 27: 74–84.Google Scholar
Kapczynski, A. 2009. “Harmonization and Its Discontents: A Case Study of Trips Implementation in India's Pharmaceutical Sector.” California Law Review 97: 1571–1650.Google Scholar
Kaplan, W. and Laing, R., 2005. “Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines, an Overview of Key Concepts, Issues and Opportunities for Future Research.” Health, Nutrition and Population (HNP) Discussion Paper.Google Scholar
Krishna, V. V. 2001. “Changing Policy Cultures, Phases and Trends in Science and Technology in India.” Science and Public Policy 28: 179–194.Google Scholar
Li, X. 2008. “The Impact of Higher Standards in Patent Protection for Pharmaceutical Industries under the TRIPs Agreement: A Comparative Study of China and India.” The World Economy 31: 1367–1382.Google Scholar
Love, J. P. 2007. “Recent Examples of the Use of Compulsory Licenses on Patents.” KEI Research Note, 2. Accessed April 27, 2012. http://www.keionline.org.Google Scholar
Lundvall, B.-Å. 1992. National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning. London: Pinter.Google Scholar
Lundvall, B.-Å. 2007. “National Innovation System. Analytical Concept and Development Tool.” Industry and Innovation 14: 95–119.Google Scholar
Mahajan, M. 2011. “The Emergence of New R&D Paradigms in the Indian Pharmaceutical Industry: Post TRIPs Period.” Journal of Intellectual Property Rights 16 (July): 321–329.Google Scholar
Malerba, F. 2005. “Sectoral Systems – How and Why Innovation differs across Sectors.” In The Oxford Handbook of Innovation, edited by Fagerberg, J., Mowery, D. C. and Nelson, R. R., 380–406. Oxford: Oxford University Press.Google Scholar
Malerba, F. and Nelson, R. 2011. “Learning and Catching up in Different Sectoral Systems: Evidence from Six Industries.” Industrial and Corporate Change 20: 1645–1675.Google Scholar
Mani, S. 2006 “The Sectoral System of Innovation of Indian Pharmaceutical Industry.” Centre for Development Studies. Working Paper No. 382, 1–59.Google Scholar
May, C. 2000. A Global Political Economy of Intellectual Property Rights. The New Enclosures? London: Routledge.Google Scholar
May, C. and Sell, S. 2006. Intellectual Property Rights. A Critical History. London: Lynne Rienner Publishers.Google Scholar
Mkandawire, T. 2007. “Transformative Social Policy and Innovation in Developing Countries.” The European Journal of Development Research 19: 13–29.Google Scholar
MoC&F (Ministry of Chemistry and Fertilizers). 2005. “National Pharmaceutical Policy.” Health Administrator XX: 1–8.Google Scholar
MoCI (Ministry of Commerce and Industry). 2008. Strategy for Increasing Exports of Pharmaceutical Products.Google Scholar
MS (Ministério da Saúde). 2011. “Acesso a Medicamentos Gratuitos Triplica No País.” Accessed September 13, 2011. http://portalsaude.saude.gov.br/portalsaude/index.cfm/?portal=pagina.visualizarNoticia&codConteudo=2309&codModuloArea=162&chamada=acesso-a-medicamentos-gratuitos-triplica-no-pais.Google Scholar
MST (Ministry of Science and Technology). 2003. Science and Technology Policy 2003.Google Scholar
Nair, M. 2008. “Compromizing Trips: Brazil's Approach to Tackle the HIV/Aids Imbroglio.” Journal of Intellectual Property Rights 13: 456–463.Google Scholar
Nassif, A. 2007. “National Innovation System and Macroeconomic Policies: Brazil and India in Comparative Perspective.” Discussion Papers United Nations Conference on Trade and Development 184: 1–38.Google Scholar
Neeraj, S. S. 2011. “India Pharmaceutical-Industry as an Export Sector.” GITAM School of International Business. Accessed September 21, 2011. http://www.scribd.com/doc/48571412/Indian-Pharmaceutical-Export-Industry on April 12.Google Scholar
Nelson, R. R. 1992. National Innovation Systems: A Comparative Analysis. Oxford: Oxford University Press.Google Scholar
Niosi, J. 2011. “Building Innovation Systems: An Introduction to the Special Section.” Industrial and Corporate Change 20: 1637–1643.Google Scholar
OSEC. 2010 “Brazil's Pharmaceutical Industry.” Accessed March 22, 2012. http://www.osec.ch/de/blog/brazil%E2%80%99s-pharmaceutical-industry-opportunities-swiss-suppliers.Google Scholar
PAHO (Pan American Health Organization) and USAID. 2008. Brazil: Health Systems and Services Profile – Monitoring and Analysis of Health Systems Change/Reform, Brasilia, D.F., Brazil.Google Scholar
Paranhos, J. 2010. Interação Entre Empresas E Instituições De Ciência E Tecnologia No Sistema Farmacêutico De Inovação Brasileiro: Estrutura, Conteúdo E Dinâmica. Rio de Janeiro.Google Scholar
PCI (Pharmacy Council of India). 2010. “National Seminar on ‘Recent Trends in Pharmacy Education and Practice’.” Accessed March 20, 2012. http://pci.nic.in/PDF-Files/14-142%20%28Seminar%29.pdf.Google Scholar
Pharmainfo. 2008, March 13. “Pharm D. Program in India.” Pharmainfo.net. Accessed March 12, 2012. http://www.pharmainfo.net/abhi271183/pharmd-program-india.Google Scholar
Presidente da Républica. 2004. Lei De Inovação.Google Scholar
Rao, J. M. 2006. Globalization, Technology and Competition: Indian Pharmaceutical Industry in the Context of the WTO. Vidyanagar, Hyderabad: Media House Publications.Google Scholar
Rezaie, R., Daar, A., Maliakkal, M., Sammut, S., Frew, S. and Singer, P. 2008. “Brazilian Health Biotech – Fostering Crosstalk between Public and Private Sectors.” Nature Biotechnology 26: 627–644.Google Scholar
Roemer-Mahler, A. 2013. “Business Conflict and Global Politics: The Pharmaceutical Industry and the Global Protection of Intellectual Property Rights.” Review of International Political Economy 20: 121–152.Google Scholar
Salama, B. and Benoliel, D. 2010. “Pharmaceutical Patent Bargains – the Brazilian Experience.” Cardozo Journal of International and Comparative Law 18: 633–682.Google Scholar
Sampat, B. 2010. Institutional Innovation or Institutional Imitation? The Impact of Trips on India's Patent Law and Practice. New York: Columbia University.Google Scholar
Sampath, P. G. 2010. “Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry.” eSocialSciences Working Papers, 3336.Google Scholar
Schüren, V. 2012. “Two TRIPs to Innovation: Pharmaceutical Innovation Systems in India and Brazil.” SFB-Governance Working Paper Series, Berlin, Research Center 700.Google Scholar
Sell, S. K. 2003. Private Power, Public Law: The Globalization of Intellectual Property Rights. Cambridge: Cambridge University Press.Google Scholar
Shadlen, K. C. 2007. “The Political Economy of Aids Treatment: Intellectual Property and the Transformation of Generic Supply.” International Studies Quarterly 51: 559–581.Google Scholar
Shadlen, K. C. 2009. “The Politics of Patents and Drugs in Brazil and Mexico: the Industrial Bases of Health Policies.” Comparative Politics 42: 41–58.Google Scholar
Spicy, IP. 2012, May 12. “Parliamentary Standing Committee on Health Tables Damning Report on the Dangerous Liaisons between the DCGI & the Pharmaceutical Industry.” Accessed May 15, 2012. http://spicyipindia.blogspot.de/2012/05/parliamentary-standing-committee-on.html.Google Scholar
Thach, S. and Marsnik, S. J. 2009. “Patent Standards under Trips and the Pharmaceutical Industries in Brazil and India.” Latin American Business Review 10: 237–261.Google Scholar
Thorsteinsdóttir, H., Quach, U., Martin, D. K., Daar, A. S. and Singer, P. A. 2004. “Introduction: Promoting Global Health through Biotechnology.” Nature Biotechnology 22: DC3–DC7.Google Scholar
Thorsteinsdóttir, H., Quach, U., Daar, A. S. and Singer, P. A. 2004a. “Conclusions: Promoting Biotechnology Innovation in Developing Countries.” Nature Biotechnology 22: DC48–DC7.Google Scholar
TOI (Times of India). 2012, February 13. “PMO Push for Free Drugs at Govt Hospitals.” Accessed April 16, 2012. http://articles.timesofindia.indiatimes.com/2012-02-13/india/31054648_1_health-care-medicines-drug-procurement.Google Scholar
Trans World News. 2011, January 6. “The Market for Pharmaceuticals in Brazil, Russia, India & China.” Accessed April 10, 2012. http://thegmd.transworldnews.com/NewsStory.aspx?id=747085&cat=0.Google Scholar
Tyfield, D. 2008. “Enabling TRIPs: The Pharma-Biotech-University Patent Coalition.” Review of International Political Economy 15: 535–566.Google Scholar
Vieira, F. S. 2009. “Ministry of Health's depending on Drugs: Program Trends from 2002–2007.” Rev Saúde Pública 43: 206–209.Google Scholar
Vieira, F. S. and Zucchi, P. 2011. “Resource Allocation for Pharmaceutical Procurement in the Brazilian Unified Health System.” Rev Saúde Pública 45: 906–913.Google Scholar
Viotti, E. B. 2002. “National Learning Systems – a New Approach on Technological Change in Late Industrializing Economies and Evidences from the Cases of Brazil and South Korea.” Technological Forecasting & Social Change 69: 653–80.Google Scholar
Wade, R. 1990. Governing the Market: Economic Theory and the Role of Government in East Asian Industrialisation. Princeton: Princeton University Press.Google Scholar
WHO. 2004. The World Medicines Situation. Geneva: WHO.Google Scholar
WIPO. 2011a. Statistical Country Profiles – India. Geneva: WIPO.Google Scholar
WIPO. 2011b. Statistical Country Profiles – Brazil. Geneva: WIPO.Google Scholar
Wright, A. 2008. Innovation in Brazil: Public Policies and Business Strategies. Washington, D.C.: Woodrow Wilson Center for Scholars.Google Scholar